SalioGen Therapeutics
Cambridge, MA
SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.
saliogen.comCompany Details
Founded
- 2020
Employees
- Between 20 - 100 employees
Raised
- $135,000,000
Headquarters Location
- Cambridge, MA
Public
- No
Acquired
- No
CEO
Jason Cole
Founders
- Joseph Higgins
Company Collections
These are collections SalioGen Therapeutics is a part of. Click on the collection name to view similar companies.
SalioGen Therapeutics' Industries
SalioGen Therapeutics Headquarters Location
Total Amount Raised: $135,000,000
SalioGen Therapeutics Funding Rounds
Series B
$115,000,000
Series B Investors
EPIQ Capital GroupGordonMD Global InvestmentsT. Rowe PriceCystic Fibrosis FoundationRD FundFidelityD1 Capital PartnersSymbiosisSeries A
$20,000,000
Series A Investors
PBM Capital Group
SalioGen Therapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on SalioGen Therapeutics.